|  |  |  | **1st dose vs. Unvaccinated** | | **3rd dose vs. 2nd dose** | |
| --- | --- | --- | --- | --- | --- | --- |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 8,521 | 8,521 | 2,983 | 2,983 |
| Age | - | Median [Q25 - Q75] | 32.00 [28.00 - 36.00] | 32.00 [28.00 - 36.00] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] |
| Age group | 12 to 24 | N (%) | 912 (10.7%) | 898 (10.5%) | 109 (3.7%) | 109 (3.7%) |
|  | 25 to 39 | N (%) | 6,858 (80.5%) | 6,879 (80.7%) | 2,546 (85.4%) | 2,546 (85.4%) |
|  | 40 to 55 | N (%) | 751 (8.8%) | 744 (8.7%) | 328 (11.0%) | 328 (11.0%) |
| Vaccine brand | Moderna | N (%) | 1,683 (19.8%) | 1,683 (19.8%) | 2,086 (69.9%) | 2,086 (69.9%) |
|  | Pfizer | N (%) | 6,838 (80.2%) | 6,838 (80.2%) | 897 (30.1%) | 897 (30.1%) |
| Trimester | Trimester 1 | N (%) | 2,199 (25.8%) | 2,201 (25.8%) | 877 (29.4%) | 874 (29.3%) |
|  | Trimester 2 | N (%) | 3,501 (41.1%) | 3,462 (40.6%) | 1,288 (43.2%) | 1,293 (43.3%) |
|  | Trimester 3 | N (%) | 2,821 (33.1%) | 2,858 (33.5%) | 818 (27.4%) | 816 (27.4%) |
| Number visits prior year | - | Median [Q25 - Q75] | 17.00 [9.00 - 29.00] | 32.00 [16.00 - 54.00] | 19.00 [10.00 - 34.00] | 34.00 [18.00 - 56.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 1.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 2,130 (25.0%) | 1,907 (22.4%) | 580 (19.4%) | 561 (18.8%) |
|  | Heart conditions | N (%) | 165 (1.9%) | 207 (2.4%) | 77 (2.6%) | 72 (2.4%) |
|  | Eclampsia preeclampsia | N (%) | 104 (1.2%) | 94 (1.1%) | 30 (1.0%) | 36 (1.2%) |
|  | Asthma | N (%) | 473 (5.6%) | 523 (6.1%) | 173 (5.8%) | 199 (6.7%) |
|  | Pneumonia | N (%) | 247 (2.9%) | 284 (3.3%) | 80 (2.7%) | 77 (2.6%) |
|  | Hypothyroidism | N (%) | 666 (7.8%) | 753 (8.8%) | 262 (8.8%) | 306 (10.3%) |
|  | Depressive disorder | N (%) | 458 (5.4%) | 493 (5.8%) | 163 (5.5%) | 160 (5.4%) |
|  | Gestational diabetes | N (%) | 503 (5.9%) | 501 (5.9%) | 147 (4.9%) | 138 (4.6%) |
|  | Chronic hypertension | N (%) | 207 (2.4%) | 201 (2.4%) | 64 (2.1%) | 74 (2.5%) |
|  | Anxiety disorder | N (%) | 2,328 (27.3%) | 2,348 (27.6%) | 816 (27.4%) | 774 (25.9%) |
|  | Chronic obstructive lung disease | N (%) | <5 (<5%) | 11 (0.1%) | <5 (<5%) | 9 (0.3%) |
| Drugs prior 180 days | Propulsives | N (%) | 341 (4.0%) | 342 (4.0%) | 102 (3.4%) | 71 (2.4%) |
|  | Progestogens | N (%) | 475 (5.6%) | 457 (5.4%) | 183 (6.1%) | 174 (5.8%) |
|  | Antimycotics systemic | N (%) | 37 (0.4%) | 46 (0.5%) | 12 (0.4%) | 12 (0.4%) |
|  | Estrogens | N (%) | 620 (7.3%) | 603 (7.1%) | 173 (5.8%) | 166 (5.6%) |
|  | Antithrombotics | N (%) | 513 (6.0%) | 383 (4.5%) | 339 (11.4%) | 196 (6.6%) |
|  | Antihistamines systemic | N (%) | 1,256 (14.7%) | 1,345 (15.8%) | 453 (15.2%) | 487 (16.3%) |
|  | Antidepressants | N (%) | 376 (4.4%) | 461 (5.4%) | 147 (4.9%) | 145 (4.9%) |
|  | Immunoglobulins | N (%) | 362 (4.2%) | 335 (3.9%) | 116 (3.9%) | 110 (3.7%) |
|  | Analgesics and antipyretics | N (%) | 2,922 (34.3%) | 2,915 (34.2%) | 1,037 (34.8%) | 970 (32.5%) |
|  | Antiinflammatory antirehumatic | N (%) | 1,273 (14.9%) | 1,290 (15.1%) | 489 (16.4%) | 488 (16.4%) |
|  | Antiepileptics | N (%) | 123 (1.4%) | 140 (1.6%) | 37 (1.2%) | 44 (1.5%) |
|  | Antibacterials systemic | N (%) | 2,000 (23.5%) | 1,991 (23.4%) | 641 (21.5%) | 589 (19.7%) |